A Study to Assess Selected Biomarkers in Subjects Requiring Daily Inhaled Corticosteroids for Persistent Asthma
A Prospective Observational Study to Assess the Role of Selected Biomarkers in Subjects Requiring Daily Medium- to High-dose Inhaled Corticosteroids for Persistent Asthma
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Faktiske)
Registrering
Kontakter og plasseringer
Studiesteder
-
-
Alberta
-
Calgary, Alberta, Canada
- Research Site
-
Edmonton, Alberta, Canada
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Research Site
-
-
Ontario
-
Toronto, Ontario, Canada
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada
- Research Site
-
Quebec City, Quebec, Canada
- Research Site
-
-
-
-
Colorado
-
Denver, Colorado, Forente stater
- Research Site
-
-
Illinois
-
Normal, Illinois, Forente stater
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Forente stater
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Forente stater
- Research Site
-
-
Missouri
-
St. Louis, Missouri, Forente stater
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater
- Research Site
-
-
Ohio
-
Columbus, Ohio, Forente stater
- Research Site
-
-
Pennsylvania
-
Pittsburg, Pennsylvania, Forente stater
- Research Site
-
-
Texas
-
Galveston, Texas, Forente stater
- Research Site
-
Houston, Texas, Forente stater
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater
- Research Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age 18 through 75 at the time of screening
- Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
- History of physician-diagnosed asthma for at least 12 months prior to screening
- Stable Medium- to high-dose ICS divided twice daily as outlined by the NHLBI Asthma Guidelines, 2007
Exclusion Criteria:
- Any medical condition that, in the opinion of the investigator or medical monitor, would interfere with interpretation of subject safety or study results
- Concurrent enrollment in another clinical study
- Use of immunosuppressive medication within 3 months prior to screening
- Acute upper or lower respiratory infections requiring antibiotics or antiviral medications with in 30 days prior to screening or during screning period.
- Receipt of immunoglobulin or blood products within 30 days prior to screening or during the screening period
- Receipt of any investigational non-biological drug therapy within 30 days or 5 half-lives prior to screening whichever is longer; or receipt of any marketed or investigational biologic within 6 months or 5 half-lives prior to screening whichever is longer
- Pregnant, lactating, or breastfeeding woman
- Diagnosis of lung disease other than persistent asthma
- History of smoking ≥10 pack years or any smoking within 12 months prior to screening
- History of active, infectious hepatitis A, B, C or human immunodeficiency virus (HIV)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Antall grupper / kohorter
Kohorter og intervensjoner
Gruppe / KohortGruppe / Kohort |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Cohort 1
50 eosinophilic subjects to be evaluated
|
Biomarker
|
|
Cohort 2
50 non-eosinophilic subjects to be evaluated
|
Biomarker
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To identify an optimal prediction rule for classifying sputum eosinophilic and non-eosinophilic asthmatics.
Tidsramme: 8 Days
|
Variables representing lung function tests, patient reported outcomes, and blood biomarkers will be evaluated singly and in various combinations.
|
8 Days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To assess which markers are associated with sputum eosinophils.
Tidsramme: 8 Days
|
Comparing lung function tests between eosinophilic and non-eosinophilic subjects.
|
8 Days
|
|
To assess which markers are associated with sputum eosinophils
Tidsramme: 8 Days
|
Comparing blood biomarkers between eosinophilic and non-eosinophilic subjects
|
8 Days
|
|
To assess which markers are associated with sputum esonophils
Tidsramme: 8 Days
|
Comparing sputum biomarkers bewteen eosinophilic and non-eosinophilic subjects
|
8 Days
|
|
To assess which markers are associated with sputum eosinophils.
Tidsramme: 8 Days
|
Comparing patient reported outcomes between eosinophilic and non-eosinophilic subjects.
|
8 Days
|
|
To evaluate transcript expression profiles in whole blood and/or sputum using microarray analyses
Tidsramme: 8 Days
|
8 Days
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Etterforskere
Etterforskere
- Studieleder: David Gossage, M.D., MedImmune LLC
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiestart
Primær fullføring (Faktiske)
Primær fullføring
Studiet fullført (Faktiske)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- MI-CP223
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .